General Partner Inc’s Idexx Laboratories IDXX Stock Holding History

General Partner Inc’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-130	Closed	-$53K	–	185
2022 Q4	$53K	Buy	+130	New	+$50.5K	0.05%	133

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

General Partner Inc's IDXX Position: Q1 2023 in Review

General Partner Inc sold out of Idexx Laboratories (IDXX) in Q1 2023, closing a stake of 130 shares — an estimated $53K sold.

General Partner Inc first reported a position in IDXX in Q4 2022 and held it in 1 quarter. The position peaked at $53K in Q4 2022. 1,055 funds tracked by Wall St. Rank hold IDXX as of Q1 2023.

General Partner Inc reported no remaining Idexx Laboratories position as of Q1 2023 after selling out during the quarter.
General Partner Inc sold 130 Idexx Laboratories shares in Q1 2023, an estimated $53K.
General Partner Inc first reported a position in Idexx Laboratories in Q4 2022 and held it in 1 quarter.
General Partner Inc's Idexx Laboratories position peaked at $53K in Q4 2022.
1,055 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2023.

Based on General Partner Inc's 13F filing for Q1 2023, filed 7 Apr 2023.